Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2026)

Revolution Medicines' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 31.22% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $30.7 million (up 31.22% YoY), while the FY2025 annual figure was $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation was $30.7 million for Q1 2026 at Revolution Medicines, up from $28.5 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $30.7 million in Q1 2026 to a low of $11.6 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $19.9 million across 5 years, with a median of $18.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation jumped 35.59% in 2023, then gained 19.86% in 2024.
• A 5-year view of Accumulated Depreciation shows it stood at $14.5 million in 2022, then gained by 22.12% to $17.7 million in 2023, then advanced by 23.34% to $21.8 million in 2024, then soared by 30.66% to $28.5 million in 2025, then advanced by 7.6% to $30.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $30.7 million (Q1 2026), $28.5 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.